Related Experiment Video

Updated: Dec 12, 2025

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

2.6K

Gastric cancer and trastuzumab: first biologic therapy in gastric cancer

Krishna S Gunturu1, Yanghee Woo, Nike Beaubier

  • 1Division of Hematology/Oncology, Tufts Medical Center, Boston, MA, USA.

Therapeutic Advances in Medical Oncology
|March 2, 2013
PubMed

Insights

Gastric cancer is hard to treat, but targeted therapies offer new hope. This review focuses on trastuzumab, a biologic therapy for human epidermal growth factor receptor 2-positive (HER2+) gastric cancer.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pharmacology

Background:

  • Gastric cancer presents significant treatment challenges with poor prognoses.
  • Current chemotherapy and multimodality treatments offer limited efficacy.
  • There is a critical need for novel therapeutic strategies, including targeted therapies.

Purpose of the Study:

  • To review the role and efficacy of trastuzumab as a biologic therapy.
  • To focus on its application in human epidermal growth factor receptor 2-positive (HER2+) gastric cancer.

Main Methods:

  • Literature review of biologic therapy in HER2+ gastric cancer.
  • Analysis of clinical data and treatment outcomes for trastuzumab.

Main Results:

  • Trastuzumab demonstrates potential as a targeted therapy for HER2+ gastric cancer.
  • Biologic therapy offers a promising alternative to conventional treatments.

Conclusions:

  • Trastuzumab represents a significant advancement in treating HER2+ gastric cancer.
  • Targeted biologic therapies are crucial for improving outcomes in gastric cancer patients.
Keywords:
gastric cancertrastuzumab

More Related Videos

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.5K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
350
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K